查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1984877

全球處方減重藥市場：按藥物分類、給藥途徑、處方類型、適應症和地區分類－市場規模、行業趨勢、機會分析和未來預測（2026-2035 年）

Global Prescription Weight Loss Medications Market: By Drug Class, Route of Administration, Prescription Type, Indication, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 270 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球處方減重藥市場持續顯著擴張，預計2025年將達到約122.5億美元。這一快速成長趨勢預計將持續，到2035年市場規模預計將飆升至約401.3億美元。這意味著在2026年至2035年的預測期內，複合年成長率約為12.60%。如此顯著的成長反映了全球肥胖症管理方式的根本性轉變，肥胖症日益被視為不僅是生活方式問題，更是治療慢性疾病的關鍵因素。

推動市場規模快速擴張的因素很多。其中最重要的因素之一是醫療保健系統日益重視預防經濟學。由於肥胖與多種慢性疾病有關，包括糖尿病、心血管疾病和某些癌症，因此投資於有效的體重管理療法被視為一種長遠的成本節約策略。透過預防或減輕這些相關疾病，醫療保健提供者和保險公司更願意支持和報銷處方減重藥，從而提振了市場需求。

顯著的市場趨勢

處方減重藥市場的投資人正日益將目光投向諾和諾德和禮來以外的公司。主要企業，旗下擁有Wegovy、Saxenda、Zepbound和Mounjaro等知名產品。儘管這兩家製藥巨頭憑藉成熟的治療方法和廣泛的市場覆蓋範圍確立了穩固的地位，但隨著新興生物技術公司和競爭對手製藥公司的進入，市場格局正在改變。

新治療方法試圖克服的主要挑戰之一是給藥頻率。目前許多減重藥物需要定期注射或每日服用，這對患者的用藥依從性帶來了挑戰。這些公司致力於研發藥效更持久、給藥方式更便捷的藥物，以提高患者的依從性並改善整體治療體驗。此外，肌肉流失是現有治療方法面臨的另一個重要問題，因為在減重過程中保持瘦體重對於維持代謝健康至關重要。

新一代減重藥物的研發可望打破目前兩大公司壟斷的局面，拓展市場機遇，這種創新主導的發展動能對投資人極具吸引力。這些新藥透過滿足未被滿足的醫療需求並改善治療方案，有望重塑市場競爭格局，為患者提供更有效、更方便的選擇，同時推動處方減重藥市場的成長和多元化發展。

主要成長要素

肥胖症盛行率的不斷上升是處方減重藥市場成長的主要驅動力。光是在美國，就有約40%的成年人被歸類為肥胖，這項數據凸顯了迫切需要採取有效干預措施來控制和減輕體重。這種趨勢並非美國獨有。世界許多地區的肥胖率都在穩步上升，加劇了全球公共衛生挑戰。隨著肥胖症患者人數的增加，人們對能夠輔助生活方式改變並實現永續減重的可靠藥物療法的需求也隨之成長。

新機會的趨勢

處方減重藥市場預計在預測期內將顯著成長，主要促進因素是保險覆蓋範圍的擴大和人均醫療費用支出的增加。隨著保險公司和政府計畫日益認知到肥胖是一個嚴重的健康問題，減重藥的保險覆蓋範圍也越來越廣。這種覆蓋範圍的擴大降低了患者的自付費用，使更多人能夠獲得這些治療。因此，更多的人將能夠在醫生的指導下接受體重管理治療，從而提振市場需求。

最佳化障礙

處方箋減重藥的高昂價格是阻礙市場整體成長的一大障礙。這些藥物價格通常很高，令大多數人難以負擔。因此，健康差距日益擴大，這些治療實際上只有高所得者才能獲得。這種差距使得那些最需要這些藥物的人，尤其是那些更容易受到肥胖影響的低收入人群，無法獲得改變人生的治療。經濟負擔不僅直接影響患者，還會影響處方模式和保險覆蓋範圍，這可能會進一步限制人們獲得治療的機會。

目錄

第1章摘要整理：全球處方減重藥市場

第2章：報告概述

  • 研究框架
    • 研究目標
    • 市場的定義
    • 市場區隔
  • 調查方法
    • 市場規模估算
    • 定性研究
    • 量化研究
    • 依地區分類的主要調查受訪者組成
    • 數據檢驗
    • 調查的前提

第3章：全球處方減重藥市場概覽

  • 產業價值鏈分析
    • 原物料供應商
    • 製造商
    • 銷售代理
    • 最終用戶
  • 產業展望
    • 全球肥胖率不斷上升
  • PESTLE分析
  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場成長及前景
    • 市場收入估算與預測（2020-2035 年）
    • 依藥品分類進行價格趨勢分析
  • 市場吸引力分析
    • 依藥物分類
    • 依地區
    • 可執行的見解（分析師建議）

第4章：競爭對手儀錶板

  • 市場集中度
  • 企業市場占有率分析（2025 年）
  • 競爭格局分析與基準測試
    • 主要企業- 依地區

第5章：全球處方減重藥市場分析

  • 市場動態和趨勢
    • 成長要素
    • 抑制因子
    • 機會
    • 主要趨勢
  • 市場機會概述
  • 依藥物分類
    • 關鍵見解
    • 市場規模及預測（2020-2035）
  • 透過行政途徑
    • 關鍵見解
    • 市場規模及預測（2020-2035）
  • 依處方類型
    • 關鍵見解
    • 市場規模及預測（2020-2035）
  • 適應症
    • 關鍵見解
    • 市場規模及預測（2020-2035）
  • 依地區
    • 關鍵見解
    • 市場規模及預測（2020-2035）

第6章：北美處方減重藥市場分析

第7章：歐洲處方減重藥市場分析

第8章：亞太地區處方減重藥市場分析

第9章：中東和非洲處方減重藥市場分析

第10章：南美處方減重藥市場分析

第11章：公司簡介

  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Merck &Co., Inc.
  • Novartis International AG
  • Novo Nordisk
  • Orexigen Therapeutics, Inc.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • VIVUS, Inc.
  • 其他主要企業

第12章附錄

簡介目錄
Product Code: AA01261687

The global prescription weight loss medication market is undergoing remarkable expansion, with its valuation reaching approximately USD 12.25 billion in 2025. This rapid growth trajectory is expected to continue robustly, with projections estimating the market will soar to around USD 40.13 billion by 2035. This represents a compound annual growth rate (CAGR) of about 12.60% over the forecast period from 2026 to 2035. Such impressive growth reflects a fundamental shift in how obesity is managed worldwide, as the condition increasingly becomes recognized not only as a lifestyle issue but as a critical component of chronic disease treatment.

Several factors are driving this surge in market value. One of the most significant is the growing emphasis on preventative economics within healthcare systems. As obesity is linked to numerous chronic diseases such as diabetes, cardiovascular conditions, and certain cancers, investing in effective weight management therapies is seen as a cost-saving strategy in the long term. By preventing or mitigating these associated illnesses, healthcare providers and payers are more willing to support and reimburse prescription weight loss medications, fueling market demand.

Noteworthy Market Developments

Investors in the prescription weight loss medications market are increasingly broadening their focus beyond the dominant players, Novo Nordisk and Eli Lilly, who currently lead the industry with their high-profile products such as Wegovy, Saxenda, Zepbound, and Mounjaro. While these two pharmaceutical giants have established a strong foothold thanks to their proven therapies and extensive market presence, the landscape is evolving as emerging biotech companies and competing pharmaceutical firms enter the scene.

One of the primary challenges that newer therapies seek to overcome is dosing frequency. Many current weight loss medications require regular injections or daily administration, which can pose adherence challenges for patients. By creating drugs with longer-lasting effects or more convenient delivery methods, these companies aim to improve patient compliance and overall treatment experience. Additionally, muscle loss is another significant concern linked to some of the existing therapies, as preserving lean body mass is crucial for maintaining metabolic health during weight loss.

This innovation-driven momentum is attracting investor interest, as the development of next-generation weight loss medications promises to expand market opportunities beyond the current duopoly. By targeting unmet needs and improving therapeutic profiles, these new assets have the potential to reshape the competitive landscape, offering patients more effective and user-friendly options while driving growth and diversification within the prescription weight loss medications market.

Core Growth Drivers

The rising prevalence of obesity stands out as a major driving force behind the growth of the prescription weight loss medications market. In the United States alone, approximately 40% of adults are classified as obese, a statistic that highlights the urgent need for effective interventions to manage and reduce excess weight. This trend is not confined to the U.S.; obesity rates are climbing steadily across many regions worldwide, contributing to a growing global public health challenge. As the number of individuals struggling with obesity increases, so too does the demand for reliable pharmacological solutions that can complement lifestyle changes and provide sustainable weight loss outcomes.

Emerging Opportunity Trends

The prescription weight loss medications market is poised for significant growth during the forecast period, driven in large part by expanded payer coverage and the rising per capita healthcare expenditures. As insurance providers and government programs increasingly recognize obesity as a critical health issue, more comprehensive coverage for weight loss medications is becoming available. This expanded payer support reduces out-of-pocket costs for patients, making these treatments more accessible to a broader population. Consequently, a larger number of individuals are able to pursue medically supervised weight management therapies, fueling market demand.

Barriers to Optimization

The high costs associated with prescription weight loss medications pose a significant barrier that may hinder the overall growth of the market. These medications often come with steep price tags, making them financially inaccessible to a large segment of the population. As a result, health inequities emerge, where only individuals with higher incomes can realistically afford these treatments. This disparity limits the reach of potentially life-changing therapies to those who need them most, particularly among lower-income groups who may be disproportionately affected by obesity. The financial burden not only affects patients directly but also influences prescribing patterns and insurance coverage decisions, which can further restrict access.

Detailed Market Segmentation

By Drug Class, GLP-1 receptor agonists secured the leading position within the prescription weight loss medications market in 2025, capturing a substantial 59% share. This dominance largely stems from the widespread clinical acceptance and proven efficacy of Semaglutide-based treatments, including well-known brands like Wegovy and Ozempic. The significant market share held by GLP-1 receptor agonists reflects what can be described as clinical inertia, where healthcare providers and patients alike continue to rely on these established medications due to their consistent performance and safety profile.

By Prescription Type, specialist prescriptions held a commanding lead in the prescription weight loss medications market, accounting for 60% of all prescriptions. This dominance is the result of a combination of interrelated factors that are driving growth within this segment. One key contributor is the severity of obesity cases seen by specialists, who often manage patients with more complex or advanced conditions that require tailored, high-efficacy treatment options. The advent of newer, more effective drugs has also played a crucial role in expanding the specialist prescription market, as these medications often require in-depth knowledge and monitoring that specialists are uniquely equipped to provide. Additionally, there has been a notable increase in the number of obesity specialists, reflecting a growing recognition of obesity as a medical condition that demands focused expertise.

  • On the indication front, obesity management emerged as the leading indication within the prescription weight loss medications market, commanding a substantial 74% share in 2025. This dominant figure represents a highly optimistic signal for the industry, reflecting a significant shift in perception among payers, regulators, and healthcare providers. Historically, weight loss treatments were often viewed primarily through the lens of Type 2 Diabetes management, with many therapies initially developed and approved for diabetic patients who also experienced weight reduction as a secondary benefit. However, the strong market share held by obesity management indicates that the industry has successfully established weight loss as a distinct, standalone therapeutic goal.
  • For route of administration, injectable formulations dominated the prescription weight loss medications market, capturing the largest share at 51%. This preference reveals an important insight into consumer psychology, where patients prioritize the effectiveness of treatment over the convenience of administration. Despite the availability of oral options, including traditional pills and early oral GLP-1 medications, the stronger clinical data supporting weight loss outcomes with subcutaneous injections has proven to be the decisive factor for many consumers. Products such as Wegovy and Zepbound, which are administered via injection, have demonstrated superior efficacy in clinical trials, making them the preferred choice for patients seeking significant and reliable weight loss results.

Segment Breakdown

By Drug Class

  • GLP-1 Receptor Agonists
  • Semaglutide
  • Liraglutide
  • Combination Therapies
  • Phentermine/Topiramate
  • Bupropion/Naltrexone
  • Appetite Suppressants/Other Pharmacotherapies
  • Emerging/Next-Gen Agents

By Route of Administration

  • Injectable Medications
  • Oral Medications

By Prescription Type

  • Specialist Prescriptions (Endocrinologists / Obesity Specialists)
  • General Practitioner Prescriptions

By Indication

  • Obesity Management
  • Weight Loss with Comorbid Condition (T2D, CVD risk)

By Region

  • North America
  • The US
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia and New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America continues to dominate the global market in terms of revenue, commanding approximately 72% of the total market value despite representing only a small portion of the world's patient population. This significant imbalance between market share and population size can largely be attributed to the region's strong pricing power. In early 2026, the Wholesale Acquisition Cost (WAC) for branded GLP-1 medications in the United States remains notably high, ranging between US$900 and $1,100 per month.
  • This price range is substantially higher than what is seen in other comparable markets such as Europe and Canada, where the same molecular entities used in prescription weight loss treatments are available at prices closer to US$150 to $300 per month. The stark contrast in pricing highlights how market dynamics, regulatory environments, and healthcare system structures in North America enable manufacturers to maintain premium pricing, driving a disproportionate share of global revenue despite serving a smaller patient base.

Leading Market Participants

  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.
  • Arena Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Novo Nordisk
  • Orexigen Therapeutics, Inc.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • VIVUS, Inc.
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Prescription Weight Loss Medications Market

Chapter 2. Report Description

  • 2.1. Research Framework
    • 2.1.1. Research Objective
    • 2.1.2. Market Definitions
    • 2.1.3. Market Segmentation
  • 2.2. Research Methodology
    • 2.2.1. Market Size Estimation
    • 2.2.2. Qualitative Research
      • 2.2.2.1. Primary & Secondary Sources
    • 2.2.3. Quantitative Research
      • 2.2.3.1. Primary & Secondary Sources
    • 2.2.4. Breakdown of Primary Research Respondents, By Region
    • 2.2.5. Data Triangulation
    • 2.2.6. Assumption for Study

Chapter 3. Global Prescription Weight Loss Medications Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Raw Material Suppliers
    • 3.1.2. Manufacturer
    • 3.1.3. Distributor
    • 3.1.4. End Users
  • 3.2. Industry Outlook
    • 3.2.1. Rising obesity rates worldwide
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis, By Drug Class
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. By Drug Class
    • 3.6.2. By Region
    • 3.6.3. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking
    • 4.3.1. Key players - By Region

Chapter 5. Global Prescription Weight Loss Medications Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Opportunity Snapshot
  • 5.3. By Drug Class
    • 5.3.1. Key Insights
    • 5.3.2. Market Size and Forecast, 2020-2035 (US$ Mn)
      • 5.3.2.1. GLP-1 Receptor Agonists
        • 5.3.2.1.1. Semaglutide
        • 5.3.2.1.2. Liraglutide
      • 5.3.2.2. Combination Therapies
        • 5.3.2.2.1. Phentermine/Topiramate
        • 5.3.2.2.2. Bupropion/Naltrexone
      • 5.3.2.3. Appetite Suppressants/Other Pharmacotherapies
      • 5.3.2.4. Emerging/Next-Gen Agents
  • 5.4. By Route of Administration
    • 5.4.1. Key Insights
    • 5.4.2. Market Size and Forecast, 2020-2035 (US$ Mn)
      • 5.4.2.1. Injectable Medications
      • 5.4.2.2. Oral Medications
  • 5.5. By Prescription Type
    • 5.5.1. Key Insights
    • 5.5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
      • 5.5.2.1. Specialist Prescriptions (Endocrinologists / Obesity Specialists)
      • 5.5.2.2. General Practitioner Prescriptions
  • 5.6. By Indication
    • 5.6.1. Key Insights
    • 5.6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
      • 5.6.2.1. Obesity Management
      • 5.6.2.2. Weight Loss with Comorbid Condition (T2D, CVD risk)
  • 5.7. By Region
    • 5.7.1. Key Insights
    • 5.7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
      • 5.7.2.1. North America
        • 5.7.2.1.1. The U.S.
        • 5.7.2.1.2. Canada
        • 5.7.2.1.3. Mexico
      • 5.7.2.2. Europe
        • 5.7.2.2.1. Western Europe
          • 5.7.2.2.1.1. The UK
          • 5.7.2.2.1.2. Germany
          • 5.7.2.2.1.3. France
          • 5.7.2.2.1.4. Italy
          • 5.7.2.2.1.5. Spain
          • 5.7.2.2.1.6. Rest of Western Europe
        • 5.7.2.2.2. Eastern Europe
          • 5.7.2.2.2.1. Poland
          • 5.7.2.2.2.2. Russia
          • 5.7.2.2.2.3. Rest of Eastern Europe
      • 5.7.2.3. Asia Pacific
        • 5.7.2.3.1. China
        • 5.7.2.3.2. India
        • 5.7.2.3.3. Japan
        • 5.7.2.3.4. South Korea
        • 5.7.2.3.5. Australia & New Zealand
        • 5.7.2.3.6. ASEAN
          • 5.7.2.3.6.1. Indonesia
          • 5.7.2.3.6.2. Malaysia
          • 5.7.2.3.6.3. Thailand
          • 5.7.2.3.6.4. Singapore
          • 5.7.2.3.6.5. Rest of ASEAN
        • 5.7.2.3.7. Rest of Asia Pacific
      • 5.7.2.4. Middle East & Africa
        • 5.7.2.4.1. UAE
        • 5.7.2.4.2. Saudi Arabia
        • 5.7.2.4.3. South Africa
        • 5.7.2.4.4. Rest of MEA
      • 5.7.2.5. South America
        • 5.7.2.5.1. Argentina
        • 5.7.2.5.2. Brazil
        • 5.7.2.5.3. Rest of South America

Chapter 6. North America Prescription Weight Loss Medications Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Drug Class
    • 6.2.2. By Route of Administration
    • 6.2.3. By Prescription Type
    • 6.2.4. By Indication
    • 6.2.5. By Country

Chapter 7. Europe Prescription Weight Loss Medications Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Drug Class
    • 7.2.2. By Route of Administration
    • 7.2.3. By Prescription Type
    • 7.2.4. By Indication
    • 7.2.5. By Country

Chapter 8. Asia Pacific Prescription Weight Loss Medications Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Drug Class
    • 8.2.2. By Route of Administration
    • 8.2.3. By Prescription Type
    • 8.2.4. By Indication
    • 8.2.5. By Country

Chapter 9. Middle East & Africa Prescription Weight Loss Medications Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Drug Class
    • 9.2.2. By Route of Administration
    • 9.2.3. By Prescription Type
    • 9.2.4. By Indication
    • 9.2.5. By Country

Chapter 10. South America Prescription Weight Loss Medications Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Drug Class
    • 10.2.2. By Route of Administration
    • 10.2.3. By Prescription Type
    • 10.2.4. By Indication
    • 10.2.5. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. AbbVie Inc.
  • 11.2. Allergan plc
  • 11.3. Amgen Inc.
  • 11.4. AstraZeneca plc
  • 11.5. Boehringer Ingelheim GmbH
  • 11.6. Eli Lilly and Company
  • 11.7. GlaxoSmithKline plc
  • 11.8. Merck & Co., Inc.
  • 11.9. Novartis International AG
  • 11.10. Novo Nordisk
  • 11.11. Orexigen Therapeutics, Inc.
  • 11.12. Pfizer Inc.
  • 11.13. Roche Holding AG
  • 11.14. Sanofi S.A.
  • 11.15. Takeda Pharmaceutical Company Limited
  • 11.16. Teva Pharmaceutical Industries Ltd.
  • 11.17. VIVUS, Inc.
  • 11.18. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators